nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—uterine cancer—cervical cancer	0.893	1	CtDrD
Medroxyprogesterone Acetate—SHBG—semen—cervical cancer	0.00588	0.101	CbGeAlD
Medroxyprogesterone Acetate—Dyspareunia—Topotecan—cervical cancer	0.00446	0.126	CcSEcCtD
Medroxyprogesterone Acetate—AR—semen—cervical cancer	0.00422	0.0727	CbGeAlD
Medroxyprogesterone Acetate—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.00312	0.0882	CcSEcCtD
Medroxyprogesterone Acetate—Acute leukaemia—Topotecan—cervical cancer	0.00285	0.0806	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—cervical cancer	0.00253	0.0437	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female gonad—cervical cancer	0.00231	0.0398	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—cervical cancer	0.00148	0.0256	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterine cervix—cervical cancer	0.00143	0.0246	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—decidua—cervical cancer	0.00136	0.0234	CbGeAlD
Medroxyprogesterone Acetate—Pelvic pain—Topotecan—cervical cancer	0.00134	0.0378	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—endometrium—cervical cancer	0.00129	0.0223	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—mammalian vulva—cervical cancer	0.00125	0.0215	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterus—cervical cancer	0.00119	0.0205	CbGeAlD
Medroxyprogesterone Acetate—Heartburn—Topotecan—cervical cancer	0.00118	0.0334	CcSEcCtD
Medroxyprogesterone Acetate—PGR—epithelium—cervical cancer	0.000975	0.0168	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—female gonad—cervical cancer	0.000973	0.0168	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endometrium—cervical cancer	0.00097	0.0167	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—cervical cancer	0.000967	0.0167	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterine cervix—cervical cancer	0.000967	0.0167	CbGeAlD
Medroxyprogesterone Acetate—PGR—decidua—cervical cancer	0.000921	0.0159	CbGeAlD
Medroxyprogesterone Acetate—Dysmenorrhoea—Topotecan—cervical cancer	0.000895	0.0253	CcSEcCtD
Medroxyprogesterone Acetate—SHBG—uterus—cervical cancer	0.000894	0.0154	CbGeAlD
Medroxyprogesterone Acetate—PGR—endometrium—cervical cancer	0.000874	0.0151	CbGeAlD
Medroxyprogesterone Acetate—Pulmonary embolism—Topotecan—cervical cancer	0.000814	0.023	CcSEcCtD
Medroxyprogesterone Acetate—PGR—uterus—cervical cancer	0.000806	0.0139	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—cervical cancer	0.000804	0.0139	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—cervical cancer	0.000777	0.0134	CbGeAlD
Medroxyprogesterone Acetate—AR—uterine cervix—cervical cancer	0.00077	0.0133	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—cervical cancer	0.000762	0.0131	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterine cervix—cervical cancer	0.000756	0.013	CbGeAlD
Medroxyprogesterone Acetate—Neoplasm—Topotecan—cervical cancer	0.000736	0.0208	CcSEcCtD
Medroxyprogesterone Acetate—AR—decidua—cervical cancer	0.000734	0.0127	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—cervical cancer	0.000731	0.0126	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—cervical cancer	0.000727	0.0125	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—cervical cancer	0.000724	0.0125	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—cervical cancer	0.00072	0.0124	CbGeAlD
Medroxyprogesterone Acetate—ESR1—decidua—cervical cancer	0.00072	0.0124	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—cervical cancer	0.000707	0.0122	CbGeAlD
Medroxyprogesterone Acetate—PGR—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.000707	0.0503	CbGpPWpGaD
Medroxyprogesterone Acetate—Sepsis—Topotecan—cervical cancer	0.000706	0.02	CcSEcCtD
Medroxyprogesterone Acetate—AR—endometrium—cervical cancer	0.000696	0.012	CbGeAlD
Medroxyprogesterone Acetate—ESR1—endometrium—cervical cancer	0.000684	0.0118	CbGeAlD
Medroxyprogesterone Acetate—AR—mammalian vulva—cervical cancer	0.000674	0.0116	CbGeAlD
Medroxyprogesterone Acetate—PGR—female gonad—cervical cancer	0.000659	0.0114	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—cervical cancer	0.000655	0.0113	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—cervical cancer	0.000642	0.0111	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—cervical cancer	0.00063	0.0109	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—cervical cancer	0.000626	0.0108	CbGeAlD
Medroxyprogesterone Acetate—Anaphylactoid reaction—Topotecan—cervical cancer	0.00061	0.0173	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—renal system—cervical cancer	0.000583	0.01	CbGeAlD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—YY1—cervical cancer	0.000578	0.0411	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—female reproductive system—cervical cancer	0.000577	0.00995	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—cervical cancer	0.000566	0.00977	CbGeAlD
Medroxyprogesterone Acetate—PGR—Nuclear Receptors—RARB—cervical cancer	0.000564	0.0401	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—endometrium—cervical cancer	0.000563	0.00971	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—cervical cancer	0.000563	0.0097	CbGeAlD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—PIAS3—cervical cancer	0.00056	0.0398	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—uterine cervix—cervical cancer	0.000558	0.00962	CbGeAlD
Medroxyprogesterone Acetate—Cramp muscle—Topotecan—cervical cancer	0.000532	0.015	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—decidua—cervical cancer	0.000531	0.00916	CbGeAlD
Medroxyprogesterone Acetate—AR—female gonad—cervical cancer	0.000525	0.00905	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—cervical cancer	0.000522	0.009	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—cervical cancer	0.000522	0.009	CbGeAlD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000521	0.0147	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—female gonad—cervical cancer	0.000515	0.00889	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—cervical cancer	0.000512	0.00883	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—endometrium—cervical cancer	0.000504	0.0087	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—mammalian vulva—cervical cancer	0.000488	0.00841	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—cervical cancer	0.000467	0.00804	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterus—cervical cancer	0.000465	0.00801	CbGeAlD
Medroxyprogesterone Acetate—Weight increased—Topotecan—cervical cancer	0.000465	0.0131	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Topotecan—cervical cancer	0.000455	0.0129	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Topotecan—cervical cancer	0.000455	0.0129	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.000446	0.0318	CbGpPWpGaD
Medroxyprogesterone Acetate—Neuropathy peripheral—Topotecan—cervical cancer	0.000446	0.0126	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000445	0.0317	CbGpPWpGaD
Medroxyprogesterone Acetate—Stomatitis—Topotecan—cervical cancer	0.000444	0.0126	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Topotecan—cervical cancer	0.000436	0.0123	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Topotecan—cervical cancer	0.00043	0.0122	CcSEcCtD
Medroxyprogesterone Acetate—AR—Nuclear Receptors—RARB—cervical cancer	0.000429	0.0306	CbGpPWpGaD
Medroxyprogesterone Acetate—Epistaxis—Topotecan—cervical cancer	0.000429	0.0121	CcSEcCtD
Medroxyprogesterone Acetate—PGR—lymph node—cervical cancer	0.000424	0.0073	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—vagina—cervical cancer	0.000422	0.00728	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—cervical cancer	0.000418	0.0072	CbGeAlD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.000415	0.0295	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—cervical cancer	0.000414	0.00715	CbGeAlD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—PIAS3—cervical cancer	0.000414	0.0294	CbGpPWpGaD
Medroxyprogesterone Acetate—Haemoglobin—Topotecan—cervical cancer	0.000411	0.0116	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Topotecan—cervical cancer	0.000409	0.0116	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Topotecan—cervical cancer	0.000406	0.0115	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—renal system—cervical cancer	0.000395	0.0068	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female gonad—cervical cancer	0.00038	0.00656	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—vagina—cervical cancer	0.000378	0.00652	CbGeAlD
Medroxyprogesterone Acetate—Angiopathy—Topotecan—cervical cancer	0.000371	0.0105	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Topotecan—cervical cancer	0.000369	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Topotecan—cervical cancer	0.000368	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Topotecan—cervical cancer	0.000367	0.0104	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Topotecan—cervical cancer	0.000361	0.0102	CcSEcCtD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—UBE3A—cervical cancer	0.000361	0.0257	CbGpPWpGaD
Medroxyprogesterone Acetate—Malnutrition—Topotecan—cervical cancer	0.000356	0.0101	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Topotecan—cervical cancer	0.000344	0.00973	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.000344	0.0245	CbGpPWpGaD
Medroxyprogesterone Acetate—Muscle spasms—Topotecan—cervical cancer	0.000342	0.00967	CcSEcCtD
Medroxyprogesterone Acetate—AR—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000339	0.0242	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.000339	0.0241	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—lymph node—cervical cancer	0.000338	0.00582	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—cervical cancer	0.000331	0.00571	CbGeAlD
Medroxyprogesterone Acetate—ESR1—Nuclear Receptors—RARB—cervical cancer	0.000331	0.0235	CbGpPWpGaD
Medroxyprogesterone Acetate—Ill-defined disorder—Topotecan—cervical cancer	0.00033	0.00934	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Topotecan—cervical cancer	0.000329	0.0093	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Nuclear Receptors—RARB—cervical cancer	0.000326	0.0232	CbGpPWpGaD
Medroxyprogesterone Acetate—Angioedema—Topotecan—cervical cancer	0.000325	0.0092	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Topotecan—cervical cancer	0.000321	0.00907	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—cervical cancer	0.000316	0.00545	CbGeAlD
Medroxyprogesterone Acetate—Arthralgia—Topotecan—cervical cancer	0.000303	0.00857	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Topotecan—cervical cancer	0.000303	0.00857	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Topotecan—cervical cancer	0.000303	0.00857	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000301	0.00851	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Topotecan—cervical cancer	0.000299	0.00846	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Topotecan—cervical cancer	0.00029	0.00821	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Topotecan—cervical cancer	0.000288	0.00816	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Topotecan—cervical cancer	0.000285	0.00805	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Topotecan—cervical cancer	0.000284	0.00804	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Topotecan—cervical cancer	0.000282	0.00798	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Topotecan—cervical cancer	0.000281	0.00794	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Topotecan—cervical cancer	0.000277	0.00783	CcSEcCtD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—UBE3A—cervical cancer	0.000267	0.019	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000264	0.00748	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000261	0.0186	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Topotecan—cervical cancer	0.000261	0.00737	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Topotecan—cervical cancer	0.000259	0.00732	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.000257	0.0183	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspepsia—Topotecan—cervical cancer	0.000256	0.00723	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—UBE3A—cervical cancer	0.000255	0.0181	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Topotecan—cervical cancer	0.000252	0.00714	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Topotecan—cervical cancer	0.000251	0.00709	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Topotecan—cervical cancer	0.00025	0.00708	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Topotecan—cervical cancer	0.000248	0.00702	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—lymph node—cervical cancer	0.000244	0.00421	CbGeAlD
Medroxyprogesterone Acetate—Feeling abnormal—Topotecan—cervical cancer	0.000239	0.00677	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Topotecan—cervical cancer	0.000237	0.00672	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Topotecan—cervical cancer	0.000231	0.00652	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Topotecan—cervical cancer	0.000229	0.00649	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Topotecan—cervical cancer	0.000229	0.00649	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Topotecan—cervical cancer	0.000214	0.00605	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Topotecan—cervical cancer	0.000208	0.00589	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Topotecan—cervical cancer	0.000205	0.00581	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—CASP3—cervical cancer	0.000202	0.0143	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Topotecan—cervical cancer	0.000199	0.00562	CcSEcCtD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—HES1—cervical cancer	0.000197	0.014	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—CTNNB1—cervical cancer	0.000194	0.0138	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Topotecan—cervical cancer	0.000192	0.00543	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Estrogen Receptor Pathway—STAT3—cervical cancer	0.000185	0.0132	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Topotecan—cervical cancer	0.000185	0.00522	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Topotecan—cervical cancer	0.000183	0.00518	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Topotecan—cervical cancer	0.000183	0.00517	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Topotecan—cervical cancer	0.000182	0.00515	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000179	0.0127	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Topotecan—cervical cancer	0.000172	0.00488	CcSEcCtD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—NOTCH1—cervical cancer	0.000149	0.0106	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—HES1—cervical cancer	0.000126	0.00899	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000118	0.0084	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000118	0.00839	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000114	0.00808	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—cervical cancer	0.000113	0.00802	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—CD4—cervical cancer	0.000111	0.00791	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—CASP8—cervical cancer	0.00011	0.00782	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—TERT—cervical cancer	9.88e-05	0.00703	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—MTOR—cervical cancer	9.21e-05	0.00655	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	9.09e-05	0.00647	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—CA9—cervical cancer	8.7e-05	0.00619	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Notch-mediated HES/HEY network—STAT3—cervical cancer	8.6e-05	0.00612	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—NOTCH1—cervical cancer	8.39e-05	0.00597	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—FGFR3—cervical cancer	8.12e-05	0.00578	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—CTNNB1—cervical cancer	8.01e-05	0.0057	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—RARB—cervical cancer	7.69e-05	0.00548	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—HES1—cervical cancer	7.54e-05	0.00536	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—cervical cancer	6.45e-05	0.00459	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	6.4e-05	0.00456	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—MTOR—cervical cancer	6.38e-05	0.00454	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	6.13e-05	0.00436	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—CTNNB1—cervical cancer	5.92e-05	0.00421	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—MTOR—cervical cancer	5.9e-05	0.0042	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—RARB—cervical cancer	5.86e-05	0.00417	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—HES1—cervical cancer	5.72e-05	0.00407	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—MTOR—cervical cancer	5.71e-05	0.00407	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—CTNNB1—cervical cancer	5.57e-05	0.00396	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CTNNB1—cervical cancer	5.53e-05	0.00393	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CTNNB1—cervical cancer	5.44e-05	0.00387	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—WNT2—cervical cancer	5.43e-05	0.00386	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—cervical cancer	5.43e-05	0.00386	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	5.32e-05	0.00378	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—STAT3—cervical cancer	5.16e-05	0.00367	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—NOTCH2—cervical cancer	5.1e-05	0.00363	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TAAR6—cervical cancer	4.87e-05	0.00347	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FGFR3—cervical cancer	4.77e-05	0.00339	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—EGFR—cervical cancer	4.69e-05	0.00334	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—STAT3—cervical cancer	4.56e-05	0.00324	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—RARB—cervical cancer	4.52e-05	0.00321	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—EGFR—cervical cancer	4.48e-05	0.00319	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—RARB—cervical cancer	4.45e-05	0.00316	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	4.41e-05	0.00314	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MTOR—cervical cancer	4.38e-05	0.00311	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CA9—cervical cancer	4.29e-05	0.00306	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—WNT5A—cervical cancer	4.12e-05	0.00293	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CASP8—cervical cancer	4.1e-05	0.00292	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	4.02e-05	0.00286	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—EGFR—cervical cancer	4.01e-05	0.00286	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CASP3—cervical cancer	3.92e-05	0.00279	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—NOTCH2—cervical cancer	3.88e-05	0.00276	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	3.88e-05	0.00276	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TAAR6—cervical cancer	3.84e-05	0.00273	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—WNT2—cervical cancer	3.8e-05	0.00271	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	3.78e-05	0.00269	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—RARB—cervical cancer	3.7e-05	0.00264	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—cervical cancer	3.68e-05	0.00262	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—cervical cancer	3.62e-05	0.00258	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—MTHFR—cervical cancer	3.53e-05	0.00251	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	3.39e-05	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MTOR—cervical cancer	3.37e-05	0.0024	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—MTOR—cervical cancer	3.35e-05	0.00239	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKAP13—cervical cancer	3.34e-05	0.00238	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	3.33e-05	0.00237	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—CTNNB1—cervical cancer	3.32e-05	0.00236	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	3.21e-05	0.00229	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—cervical cancer	3.19e-05	0.00227	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—NOTCH1—cervical cancer	3.15e-05	0.00225	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	3.1e-05	0.00221	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	3.07e-05	0.00219	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—WNT2—cervical cancer	3e-05	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—NOTCH2—cervical cancer	2.99e-05	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	2.99e-05	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CASP3—cervical cancer	2.97e-05	0.00212	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—NOTCH2—cervical cancer	2.95e-05	0.0021	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Adipogenesis—STAT3—cervical cancer	2.89e-05	0.00206	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—WNT5A—cervical cancer	2.88e-05	0.00205	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	2.87e-05	0.00204	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—RARB—cervical cancer	2.82e-05	0.00201	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKAP13—cervical cancer	2.63e-05	0.00187	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—cervical cancer	2.58e-05	0.00184	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.57e-05	0.00183	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.55e-05	0.00181	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.48e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NOTCH2—cervical cancer	2.45e-05	0.00175	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—NOTCH1—cervical cancer	2.4e-05	0.00171	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HES1—cervical cancer	2.37e-05	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	2.37e-05	0.00168	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—EGFR—cervical cancer	2.36e-05	0.00168	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—WNT5A—cervical cancer	2.27e-05	0.00162	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TAAR6—cervical cancer	2.26e-05	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—RARB—cervical cancer	2.17e-05	0.00155	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—RARB—cervical cancer	2.14e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.14e-05	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTHFR—cervical cancer	2.08e-05	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—TERT—cervical cancer	2.08e-05	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOTCH2—cervical cancer	2.02e-05	0.00144	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—cervical cancer	1.99e-05	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.96e-05	0.0014	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—FGFR3—cervical cancer	1.9e-05	0.00136	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NOTCH2—cervical cancer	1.87e-05	0.00133	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—NOTCH1—cervical cancer	1.85e-05	0.00132	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—NOTCH1—cervical cancer	1.82e-05	0.0013	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOTCH1—cervical cancer	1.79e-05	0.00127	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—WNT2—cervical cancer	1.76e-05	0.00125	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—MTHFR—cervical cancer	1.74e-05	0.00124	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HES1—cervical cancer	1.66e-05	0.00118	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.65e-05	0.00117	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOTCH2—cervical cancer	1.6e-05	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKAP13—cervical cancer	1.55e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NOTCH1—cervical cancer	1.52e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TERT—cervical cancer	1.45e-05	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NOTCH2—cervical cancer	1.44e-05	0.00102	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NOTCH2—cervical cancer	1.42e-05	0.00101	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTOR—cervical cancer	1.34e-05	0.000953	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CD4—cervical cancer	1.34e-05	0.000952	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—WNT5A—cervical cancer	1.33e-05	0.000949	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FGFR3—cervical cancer	1.33e-05	0.000949	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HES1—cervical cancer	1.31e-05	0.000931	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOTCH1—cervical cancer	1.25e-05	0.000891	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CA9—cervical cancer	1.21e-05	0.000859	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—cervical cancer	1.19e-05	0.000845	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NOTCH1—cervical cancer	1.16e-05	0.000824	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TERT—cervical cancer	1.15e-05	0.000816	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FGFR3—cervical cancer	1.05e-05	0.000749	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—STAT3—cervical cancer	1.04e-05	0.000737	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOTCH1—cervical cancer	9.88e-06	0.000703	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CA9—cervical cancer	9.83e-06	0.000699	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EGFR—cervical cancer	9.41e-06	0.00067	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MTOR—cervical cancer	9.38e-06	0.000668	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH2—cervical cancer	9.36e-06	0.000666	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NOTCH1—cervical cancer	8.91e-06	0.000634	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NOTCH1—cervical cancer	8.78e-06	0.000625	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP3—cervical cancer	8.63e-06	0.000614	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—cervical cancer	8.32e-06	0.000592	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HES1—cervical cancer	7.68e-06	0.000546	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MTOR—cervical cancer	7.4e-06	0.000527	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—cervical cancer	7.25e-06	0.000516	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—cervical cancer	6.81e-06	0.000484	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—cervical cancer	6.73e-06	0.000479	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—cervical cancer	6.59e-06	0.000469	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—cervical cancer	6.56e-06	0.000467	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA9—cervical cancer	6.48e-06	0.000461	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR3—cervical cancer	6.17e-06	0.000439	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH1—cervical cancer	5.8e-06	0.000412	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—cervical cancer	5.72e-06	0.000407	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—cervical cancer	5.53e-06	0.000394	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—cervical cancer	5.2e-06	0.00037	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—cervical cancer	4.9e-06	0.000349	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—cervical cancer	4.36e-06	0.000311	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTOR—cervical cancer	4.34e-06	0.000309	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—cervical cancer	3.99e-06	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—cervical cancer	3.99e-06	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—cervical cancer	3.85e-06	0.000274	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—cervical cancer	3.36e-06	0.000239	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—cervical cancer	3.05e-06	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—cervical cancer	2.63e-06	0.000187	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—cervical cancer	2.56e-06	0.000182	CbGpPWpGaD
